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Abstract
BACKGROUND & AIMS—Despite the significant association between obesity and several 
cancers, it has been difficult to establish an association between obesity and hepatocellular 
carcinoma (HCC). Patients with HCC often have ascites, making it a challenge to accurately 
determine body mass index (BMI), and many factors contribute to the development of HCC. We 
performed a case–control study to investigate whether obesity early in adulthood affects risk, age 
of onset, or outcomes of patients with HCC.
METHODS—We interviewed 622 patients newly diagnosed with HCC from January 2004 
through December 2013, along with 660 healthy controls (frequency-matched by age and sex) to 
determine weights, heights, and body sizes (self-reported) at various ages before HCC 
development or enrollment as controls. Multivariable logistic and Cox regression analyses were 
performed to determine the independent effects of early obesity on risk for HCC and patient 
outcomes, respectively. BMI was calculated, and patients with a BMI ≥30 kg/m2 were considered 
obese.
RESULTS—Obesity in early adulthood (age, mid-20s to mid-40s) is a significant risk factor for 
HCC. The estimated odds ratios (OR) and 95% confidence intervals (CI) were 2.6 (1.4–4.4), 2.3 
(1.2–4.4), and 3.6 (1.5–8.9) for the entire population, men, and women, respectively. Each unit 
increase in BMI at early adulthood was associated with a 3.89-month decrease in age at HCC 
diagnosis (P<.001). Moreover, there is a synergistic interaction between obesity and hepatitis virus 
infection. However, we found no effect of obesity on the overall survival of patients with HCC.
CONCLUSION—Early adulthood obesity is associated with increased risk of developing HCC at 
a young age in the absence of major HCC risk factors, with no effect on outcomes of patients with 
HCC.
Keywords
obesity; HCC; case-control; risk factor
INTRODUCTION
Overweight and obesity are major public health problems in both economically developed 
and developing countries. Between 1980 and 2013, the global prevalence of overweight and 
obesity combined increased by 27.5% for adults and 47.1% for children.1 The increase was 
higher in developed than in developing countries. If such trends continue, by 2030, up to 
57.8% of the world’s adult population could be either overweight or obese.2
Concurrent with the increased rate of obesity in the United States, the incidence of 
hepatocellular carcinoma (HCC) has significantly increased over the past 3 decades,3, 4 with 
a positive correlation observed between prevalence of obesity and incidence of HCC.5, 6
Despite the reported significant association between obesity and several cancers in the 
United States,7 the association between obesity and HCC8, 9 has been difficult to confirm for 
the following reasons: 1) rarity and poor prognosis of HCC, making large-scale studies 
difficult to conduct; 2) underlying cirrhosis associated with portal hypertension and ascites 
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that can preclude accurate assessment of body mass index (BMI) at the time of HCC 
diagnosis; 3) missing BMI estimates in medical records of HCC patients; and 4) the 
multifactorial origin of HCC, necessitating adjustments for the confounding effects of the 
major HCC risk factors including hepatitis C virus (HCV), hepatitis B virus (HBV), diabetes 
mellitus, and alcohol consumption.
To investigate the association between HCC and obesity before HCC development, we 
embarked on a large case-control study in which we integrated clinical and epidemiological 
data with obesity data to assess 1) the independent effect of excess body weight across an 
individual’s life cycle on HCC risk, 2) the synergistic interaction between obesity and other 
HCC risk factors, and 3) the effect of obesity on age at HCC onset or on overall survival rate 
of HCC patients.
METHODS
This investigation was part of an active hospital-based case-control study, which was 
approved by the Institutional Review Board at The University Texas MD Anderson Cancer 
Center (Protocol # ID00-083). Written informed consent for participation was obtained from 
each participant.
Case patients were recruited from the population of patients with newly diagnosed HCC 
who were evaluated and treated at MD Anderson Cancer Center’s gastrointestinal medical 
oncology and surgical oncology outpatient clinics. The inclusion criteria were a 
pathologically or radiologically confirmed diagnosis of HCC and U.S. residency. The 
exclusion criteria were the presence of other types of primary liver cancer (such as 
cholangiocarcinoma or fibrolamellar hepatocarcinoma), unknown primary tumors, and 
concurrent or past history of cancer at another organ site.
Control subjects were healthy (cancer-free) and genetically unrelated family members (such 
as spouses) of cancer patients at MD Anderson. However, we excluded family members and 
spouses of patients with liver, gastrointestinal, lung, or head and neck cancer. The reason for 
such exclusion was to prevent the introduction of selection bias connected with shared 
environmental and genetic factors that are highly associated with HCC, e.g., alcohol 
consumption, smoking, family history of cancer, and hepatitis virus infection. Cases and 
controls were frequency-matched by age (±5 years) and sex. Between January 2004 and 
December 2013, 622 HCC case patients and 660 control subjects participated in this 
investigation. HCC patients and controls were recruited simultaneously and were 
interviewed in person for demographic features and HCC risk factors (Table 1) with use of a 
structured and validated questionnaire. We defined cigarette smokers as subjects who had 
smoked ≥100 cigarettes during their lifetime. Heavy smokers were defined as those who had 
>20 pack-years of smoking. We defined ever-alcohol drinkers as subjects who had 
consumed at least 4 alcoholic drinks each month for 6 months in their lifetime. We further 
classified ever-drinkers according to the total lifetime volume of ethanol consumed in 
milliliters, which was computed according to the frequency of drinking, type of serving 
(glass, bottle, or can), number and size of each serving, and duration of consumption, 
summed over the whole period of alcohol use. Heavy alcohol consumption was defined as 
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consumption of more than 60 mL of ethanol/day during the subject’s period of alcohol 
drinking.10
Participants were interviewed for history of diabetes mellitus, type of diabetes, age at 
diagnosis, and duration of diabetes. Subjects with a history of diabetes were questioned 
about medications used for diabetes control and the duration of treatment, and reported 
results of HbA1. Information about prior history of chronic liver diseases (CLDs) was 
obtained including cirrhosis, hemochromatosis, primary biliary cirrhosis, Wilson disease, 
autoimmune hepatitis, and alpha 1 antitrypsin deficiency. A detailed questionnaire about 
obesity was included during the interview to obtain information about self-reported height 
(inches) and weight (pounds) across the life cycle before cancer diagnosis (HCC patients) or 
before recruitment (controls), including current weight as well as weight when patients and 
controls were in their mid-20s, mid-30s, mid-40s, mid-50s, and mid-60s. In addition, self-
reported body size across the same ages using the validated Stunkard pictograms was 
obtained from each participant. BMI was calculated [(weight (kg)/height (m)2] and 
classified as a four-level categorical variable: underweight (<18.5 kg/m2), normal weight 
(18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), or obese (≥30 kg/m2). Only 4 HCC 
patients were classified as underweight and were included among the normal weight 
category.
All participants were questioned to classify their past engagement in physical activity (at 
work or free time), as well as the type, frequency, and duration of activities during the past 5 
years. Vigorous physical activity was described as enough to get sweaty, experience fast 
heart beats, or get out of breath. All cases and controls recalled their family history of all 
cancers among first- and second-degree relatives.
Detailed clinical variables were retrieved from HCC patients’ medical records; these 
variables included information about different HCC staging scores, HCC treatment 
exposure, pathological differentiation, underlying cirrhosis, vascular invasion, metastasis, 
lymph node involvement, tumor nodularity and size, and alpha fetoprotein level.11–13 
Overall survival (OS) was defined as the time between HCC diagnosis and death (as a result 
of all causes) or end of follow-up (censored observations). Underlying cirrhosis was 
determined by pathological findings (diagnostic biopsies) and by computed tomography 
scans. In addition, all HCC patients were examined for the signs of cirrhosis including 
manifestations related to portal hypertension, e.g. ascites, bleeding from esophageal varices, 
and hepatic encephalopathy. Minor signs were also noted clinically, such as palmar 
erythema, spider angioma, and clubbing of the fingers.
Blood samples from cases and controls were tested for HBV and HCV. HCV antibodies, 
hepatitis B surface antigen, and antibodies to hepatitis B core antigen were detected by use 
of a third-generation enzyme-linked immunosorbent assay (ELISA) (Abbott Laboratories, 
North Chicago, IL). Positive results prompted repeated confirmatory ELISA testing.
Stata software (Stata Corp, College Station, TX) was used for statistical analysis. We 
performed multivariate unconditional logistic regression analyses. For each risk factor, we 
calculated the adjusted odds ratio (OR) and 95% confidence interval (CI) values, using 
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maximum likelihood estimation. All ORs for the association between BMI and HCC were 
adjusted for age, sex, race, educational level, smoking, alcohol, diabetes, family history of 
cancer, physical activity, and HBV or HCV infection. Hazard ratios (HRs) and 95% CIs 
were calculated by using Cox proportional hazard models. The population-attributable risk 
percentage (PAR%) of HCC was calculated, as follows: , in 
which OR is the adjusted OR for the relationship between being obese and having HCC, and 
Pe is the prevalence of being obese in the control population in the early adulthood period 
before enrollment.
Analysis of covariance was used to analyze patients’ mean age at HCC onset by BMI status. 
Linear regression models were used to estimate the mean differences in age at HCC onset 
associated with BMI after adjusting for other factors associated with age at onset in this 
study population.
We used multiple logistic regression models to investigate possible interactions on an 
additive scale of prior adulthood history of obesity with hepatitis virus infection (HCV and 
HCV), alcohol consumption, and diabetes mellitus. To assess deviation from the additive 
model (which assumes no interaction between variables), we calculated the synergism index 
, in which OR11 = OR of the joint effect of two risk factors, and OR10 
and OR01 = OR of each risk factor in the absence of the other. A value of S equal to unity 
was indicative of additivity, whereas a value greater than unity was indicative of 
superadditivity and synergism.14, 15
RESULTS
The baseline demographic characteristics of patients and controls are summarized in table 1. 
Most study subjects were non-Hispanic white men; the men-to-women ratio was 3.2 to 1 for 
HCC patients. Case patients were slightly older than control subjects, with a mean difference 
of 3 years (95% CI, 2 to 5); the mean [± standard error (SE)] ages were 63 ± .4 years for 
HCC patients and 60 ± .4 years for controls. Higher education (≥ college degree) was more 
frequent among control subjects than among HCC patients. Cases and controls had a similar 
distribution of geographical region (US state of residency) where 369 (59.3%) cases and 401 
(60.8%) controls were from state of Texas, P =.1.
This study continued to support the association between HCC and several risk factors 
reported previously by us16–19 and by other investigators, including alcohol drinking, 
cigarette smoking, diabetes mellitus, HCV, HBV, and family history of cancer.20–24
Figure 1A shows the distribution of overweight and obesity among HCC cases and controls 
at ages ranging from their mid-20s to mid-60s.
The prevalence of ever experience of obesity during lifetime was recalled by 38.4% (95% 
CI, 33.7%–43.4%) of HCC case patients and by 30.6% (95% CI, 27.1%–34.3%) of healthy 
controls (P = .03).
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We calculated the average BMI during early adulthood (mid-20s to mid-40s) and then 
classified BMI into normal, overweight, and obese. The prevalence of obesity (BMI ≥30) in 
early adulthood (mid-20s to mid-40s) was significantly higher in HCC cases than in controls 
(Figure 1B; P = .002). Table 2 shows that among all study subjects, more cases (21.8%) than 
controls (18.7%) reported overweight in their mid-20s (P = .02). A prior history of obesity 
in the mid-20s, mid-30s, and mid-40s was significantly associated with increased HCC risk 
in the whole study population and in absence of major HCC risk factors (Table 2).
Table 3 shows that the mean age at HCC onset among case patients who recalled a prior 
history of early adulthood obesity in their mid-20s to mid-40s was significantly lower than 
the mean age at onset of those with normal BMIs at the same life cycle (P = .01, <.001, <.
001, respectively). For example, in those with obesity history in their mid-20s, HCC was 
diagnosed more than 3 years sooner than in those at normal weight. The mean ages (years ± 
SD) at diagnosis were 63.4 (±11.19), 63.0 (±10.6), and 60.1 (±11.6) years for those in their 
mid-20s who were normal weight, overweight, and obese, respectively. We observed similar 
results when we examined the mean age at HCC onset in patients in their mid-30s and 
mid-40s, comparing those who were obese/overweight with those with normal weight. The 
mean difference in age at HCC onset between obese individuals and those with normal body 
weight was determined to be statistically significant after adjusting for other factors 
associated with age at HCC onset (Table 3). We estimated that each 1-unit increase in BMI 
at early adulthood (mid-20s to mid-40s) before HCC diagnosis was associated with a 3.89-
month decrease in the age at HCC diagnosis (P = <.001). The estimated coefficient = −3.89 
and 95% CI (−5.60 to −2.18) after controlling for the confounding effect of HCC risk factors 
(P < .0001).
Only 12% of obese cases and 4% of obese controls recalled weight reduction over time; 
among whom 6% of the case patients and 2% of the controls experienced ≥ 10% weight 
reduction. These reductions had no significant effect on the risk of HCC development.
Restricted analyses among white subjects, men, women, nondrinkers, non-HCV/-HBV–
infected subjects, nondiabetics, and nonsmokers indicated no significant association between 
early adulthood overweight (mid-20s to mid-40s) with HCC development (Figure 2A). 
However, the odds for developing HCC are approximately 2- to 4-fold greater for subjects 
with early adulthood obesity than for subjects with normal BMI (Figure 2B). A total of 21 
HCC cases and 0 controls recalled a prior history of CLD; excluding these cases from 
analysis did not meaningfully change the significant association between early adulthood 
obesity and HCC.
Table 4 shows the relative excess risk for patients having prior history of early adulthood 
obesity (mid-20s to mid-40s) and HCV/HBV, alcohol consumption, or diabetes mellitus. By 
crossing each risk factor with early adulthood obesity (mid-20s to mid-40s), a dummy 
variable of 4 categories was obtained: two for the presence of each factor in the absence of 
the other, one indicating the presence of joint factors, and one for unexposed to either factor. 
The “unexposed to either factor” category was used as the reference category in the 
regression model. For example, the ORs (95% CI) for hepatitis virus infection in the absence 
of obesity, obesity in the absence of virus infection, and combined virus infection and 
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obesity were 31.7 (19.3–52.3), 2.5 (1.5–4.3), and 72.5 (9.2–574.2), respectively. Using the 
OR as an estimate for the relative risk of disease development, the relative excess risk for 
patients having early adulthood obesity plus hepatitis virus infection exceeded the sum of 
the relative excess risks for the virus infection and obesity alone, that is, 72.5−1.0 > 
(31.7−1.0) + (2.5−1.0), indicating a departure from additivity in the joint effect of early 
adulthood obesity with HCV/HBV (S = 2.2; 95% CI, 1.2–3.9). This may suggest that 
obesity, in addition to its own direct effects, may exacerbate the effect of chronic hepatitis 
virus infection on HCC. A similar approach was performed for the joint effect of diabetes 
and alcohol consumption with early adulthood obesity. Unlike with hepatitis virus infection 
(HCV/HBV), we found no risk modification for the joint effect between alcohol 
consumption or diabetes mellitus with early adulthood obesity (mid-20s to mid-40s) (Table 
4).
In our control group, the prevalence of diabetes, early adulthood obesity, and combined 
diabetes with early adulthood obesity were 9.85%, 5%, and 2.12%, respectively. Therefore, 
according to the ORs values in Table 4, the estimated PARs% were 21% for diabetes, 10% 
for early adulthood obesity, and 11% for the combination of diabetes and early adulthood 
obesity.
The clinical features of HCC did not significantly vary by the status of early adulthood BMI 
(normal, overweight, obese) (Table 5). The estimated median OS (95% CI) values were 21.9 
(18.7–25.2), 18.9 (13.2–24.8), and 19.9 (16.7–23.2) for normal BMI, overweight, and 
obesity, respectively (P = .6). In addition, multivariate Cox regression analysis indicated that 
early adulthood obesity (mid-20s to mid-40s) was not associated with a significantly 
increased total mortality (HR = .9; 95% CI, .6–1.4) (P = .6).
DISCUSSION
The current study is, to our knowledge, the first to show that obesity in early adulthood 
(mid-20s to mid-40s) in both men and women is associated with increased risk of HCC 
development and with early onset of HCC, regardless of the confounding effects of the 
established risk factors of HCC such as HCV, HBV, alcohol consumption, cigarette 
smoking, and diabetes mellitus.
Approximately 42% of our HCC cases could be explained by obesity and diabetes, which 
was comparable to the 38.9% reported by the McGlynn group.25 However, the uniqueness 
of our study is its ability to analyze diabetes and obesity separately, specifically, in 
determining that 10% of the HCC cases in our study could be attributed to early adulthood 
obesity independent from diabetes mellitus or other HCC risk factors.
The association between increased body weight and liver cancer has been determined 
through meta-analyses and systematic reviews.8, 9, 25–28 One potential limitation of these 
review studies, which is highlighted by their authors, is that many of the individual studies 
did not adjust for the major risk factors of HCC, including HCV, HBV, diabetes, and alcohol 
consumption.29 In addition, population selection in the individual studies in these reviews 
was not exclusive to a diagnosis of HCC. Also, relying on BMI at the time of case 
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ascertainment (HCC diagnosis) from case-control studies is subject to miscalculation 
(overestimation) because of the presence of ascites among many HCC patients with 
underlying cirrhosis. Moreover, in the included cohort studies, BMI had been estimated at 
initial enrollment and weight change monitored for only a small number of patients with 
HCC.
The potential biological mechanism for the association between obesity and HCC can be 
related to a number of physiological changes.30–32 Obese individuals often experience 
hepatic steatosis with potential progression to steatohepatitis and cirrhosis.33, 34 Key 
transcription factors in fatty acid oxidation, such as peroxisome proliferator-activated 
receptors, may play a dual role in hepatocellular proliferation and in cyclooxygenase-2 
expression, which may explain terminal disease progression from steatohepatitis to HCC.35 
Yet, cirrhosis is not the only explanation for the association between obesity and HCC. In 
this study, we found that ~62% of HCC patients had underlying cirrhosis and that among 
these patients, there were no significant differences in the proportions with normal weight, 
overweight, or obesity. Many obese individuals develop some degree of insulin resistance 
with elevated insulin-like growth factors,36 which may have tumorigenic activity and have a 
role in cell growth/proliferation and fatty degeneration.37
Several studies have examined the association between obesity and clinical outcome in 
various cancers including HCC.38–42 However, HCC studies have shown that mortality was 
not influenced by BMI.40, 43 Moreover, the association between obesity and life-threatening 
morbidities and complications after hepatic resection has not been conclusive, with some 
studies suggesting that hepatic resection in overweight and obese HCC patients is 
safe.39, 41, 42
The reasons for the poor prognosis observed in obese cancer patients is unclear but can be 
correlated with comorbidities or cancer consequences typically seen in obese patients such 
as heart diseases.41 Other pathways have been hypothesized including the observed low 
level of adiponectin in men and women with high BMI44; in fact, a more favorable 
prognosis was observed in HCC patients with higher expression of adiponectin.45, 46 In 
addition, angiogenesis dysregulation induced by the adipose tissue through leptin expression 
has been suggested.47 Siegel and colleagues showed that obesity is associated with 
microvascular invasion, resulting in poor HCC survival.48 In our study, vascular invasion 
was observed more frequently in overweight and obese patients than in normal-weight 
patients, but the differences were not statistically significant.
Increased risk of HCC associated with obesity was previously reported for chronic carriers 
of HBV and HCV49 and for alcohol drinkers,50 suggesting that obesity-induced oxidative 
stress may increase the liver’s susceptibility to chronic inflammation, DNA damage, fatty 
liver, and cirrhosis progression.50,34
The current study has some limitations, specifically, 1) the use of hospital-based case 
patients, many of whom were diagnosed as having advanced-stage disease, and 2) the use of 
weight and height data recalled from the distant past. Given the poor prognosis of this 
cancer, it is difficult to rely on a population-based design for recruiting patients with newly 
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diagnosed HCC for a large-scale clinico-epidemiological study. To minimize ascertainment 
or selection bias related to misdiagnosis of case patients, we chose to use a hospital-based 
design, in which all cases had a confirmed diagnosis of HCC. Similar to the natural history 
of HCC where majority of the patients are presented with advanced stage,51–54 
approximately 64% of our patients are diagnosed as having advanced-stage disease (TNM 
III–IV) at time of initial evaluation.
Control subjects were selected to represent the population from which the HCC patients 
were ascertained. Only U.S. patients and controls were included, and the geographic 
distribution of their residential states was similar. Therefore, it is unlikely that our findings 
were confounded by selection bias of cases or controls. The prevalence of ever history of 
obesity during lifetime in the control group was 30.6%, which is consistent with the recently 
reported U.S. estimate by Ng and colleagues.1
All participants were personally interviewed to obtain information about self-reported 
weight across the life cycle before cancer diagnosis (HCC patients) or before recruitment 
(controls). We observed consistent agreement in interview response between self-reported 
weight and body size (Stunkard pictograms) across different ages for HCC cases and healthy 
controls. Moreover, we found no discrepancy between interview information and patients’ 
records with respect to HCC risk factors. There was strong evidence supporting the 
reliability and validity of self-reported diabetes mellitus, where agreement between self-
reported disease diagnosis and medical conditions was observed.55–57 In addition, several 
studies reported high correlations between recalled and measured weight and height in 
young adulthood among middle-aged and older men and women.58–62
The current study continues to show the multifactorial origin of HCC. Variation in the 
magnitude of ORs for the association between environmental exposures and HCC in various 
epidemiological studies, including our early study, could be partially explained by the type 
of controls included in the study, that is, healthy versus sick controls.19 Another explanation 
was lack of quantitative assessment of environmental exposures including alcohol 
consumption and cigarette smoking by some studies. Consideration of diabetes duration 
with the exclusion of patients with a recent diagnosis may have affected the magnitude of 
reported ORs of HCC risk factors.
In conclusion, this study provides robust epidemiological evidence to support the association 
between obese adults in their mid-20s to mid-40s and risk of HCC in American men and 
women, with obese subjects more susceptible than non-obese subjects to early-onset HCC.
Educational interventions and public awareness may be key to reducing the incidence of 
obesity at a young age. Behavioral modification, including abstaining from alcohol and 
restricting diet, especially among patients with chronic viral infection, may reduce the 
incidence of end-stage CLDs.
The effect of obesity on viral activity and the treatment response of HCV and HCC among 
these high-risk patients has not yet been investigated. In addition, experimental studies are 
warranted to describe the underlying mechanisms responsible for the effect of obesity on 
HCC in the absence of cirrhosis. Finally, future investigation of the preventive and favorable 
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prognostic role of metformin and statin in patients with CLDs including HCC should be 
initiated.
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Figure 1. 
(A) Frequency of overweight and obesity at various ages during the life cycle before 
hepatocellular carcinoma diagnosis or control recruitment.
(B) Distribution of body mass index status by percentages (overweight, obese) by HCC risk 
factors in cases and controls in their mid-20s to mid-40s.
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Figure 2. 
(A) Odds Ratio, 95% Confidence Interval for the association between adulthood overweight 
(mid-20s to mid-40s) with hepatocellular carcinoma risk in the absence of major risk factors 
and with adjustment of confounding factors.
(B) Odds Ratio, 95% Confidence Interval for the association between adulthood obesity 
(mid-20s to mid-40s) with hepatocellular carcinoma risk in the absence of major risk factors 
and with adjustment of confounding factors.
Example: The estimated odds ratios, 95% confidence intervals for the association between 
adulthood overweight/obesity and HCC among non-diabetics were .9 (.6–1.4), P=.8 and 3.0 
(1.5–5.8), P=.001 respectively, after adjustment for confounding factors including age, 
ethnicity, HCV, HBV, education level, alcohol drinking, cigarette smoking, physical 
activity, and family history of cancer.
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Table 5
Distribution of hepatocellular carcinoma clinical features by BMI status at early adulthood (mid-20s to 
mid-40s)
Clinical Feature* Normal
N=360 (%)
Overweight
N=187 (%)
Obese
N= 75(%) P value
†
Presence of Cirrhosis .1
Yes 214 (59.6) 128 (68.4) 43 (57.3)
No 145 (40.4) 59 (31.6) 32 (42.7)
Evidence of Vascular Invasion 0.2
Yes 107 (29.8) 70 (37.4) 25 (33.3)
No 252 (70.2) 117 (62.6) 50 (66.7)
Evidence of Portal Thrombosis 0.7
Yes 82 (22.8) 49 (26.2) 19 (25.3)
No 277 (77.2) 138 (73.8) 56 (74.7)
Extra-hepatic Metastasis 0.9
Yes 95 (26.5) 47 (25.1) 21 (28)
No 264 (73.5) 140 (74.9) 54 (72)
Lymph Node Involvement
Yes 60 (16.8) 45 (24.1) 17 (22.7) 0.1
No 298 (83.2) 142 (75.9) 58 (77.3)
Tumor Involvement
>50% 71 (20.4) 41 (22.2) 23 (31.1) 0.2
≤50% 272 (78.2) 143 (77.3) 51 (68.9)
Tumor Nodularity 0.4
Multi-nodular 222 (62) 109 (58.3) 50 (66.7)
Solitary-nodule 119 (33.2) 75 (40.1) 24 (32)
Performance Status 0.1
(≥ 2) 44 (12.2) 24 (12.8) 9 (12)
(< 2) 316 (87.8) 163 (87.2) 66 (88)
Tumor Differentiation 0.1
Well-Differentiated 83 (23.1) 49 (26.4) 19 (25.3)
Moderate-Differentiated 114 (31.7) 54 (29) 24 (32)
Poor-Differentiated 44 (12.2) 35 (18.8) 8 (10.7)
Not Reported 113 (31.4) 48 (25.8) 24 (32)
CLIP 0.2
CLIP Score (0–2) 276 (79.5) 138 (74.6) 50 (67.6)
CLIP Score (3) 40 (11.5) 29 (15.7) 14 (18.9)
CLIP Score (4–6) 27 (7.8) 17 (9.2) 10 (13.5)
Okuda 0.1
Stage-I 211 (58.9) 93 (49.7) 34 (45.3)
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Clinical Feature* Normal
N=360 (%)
Overweight
N=187 (%)
Obese
N= 75(%) P value
†
Stage-II 132 (36.9) 88 (47.1) 37 (49.3)
Stage-III 11 (3.1) 5 (2.7) 4 (5.3)
BCLC 0.3
Early Stage (0-A) 27 (7.5) 10 (5.3) 3 (4)
Intermediate Stage (B) 66 (18.3) 35 (18.7) 13 (17.3)
Advances Stage (C) 241 (66.9) 136 (72.7) 52 (69.3)
End Stage (D) 17 (4.7) 4 (2.1) 7 (9.3)
TNM 0.8
I–II 119 (33) 60 (32.1) 21 (28)
IIIA-IIIB-IIIC 93 (25.9) 55 (29.4) 24 (31.9)
IVA–IVB 131(36.4) 67 (35.8) 27 (36)
Treatment 0.4
Surgery and Transplant 58 (16.1) 21 (11.2) 8 (10.7)
Ablation Therapy 11 (3.1) 7 (3.7) 3 (4)
Local Therapy 118 (32.8) 69 (36.9) 19 (25.3)
Systemic Therapy 153 (42.5) 78 (41.7) 37 (49.3)
No therapy 20 (5.6) 12 (6.4) 8 (10.7)
AFP (> 400 ng/ml) 125 (34.7) 56 (29.9) 34 (45.3) 0.1
Abbreviations: Tumor–Nodes–Metastases (TNM), Cancer of the Liver Italian Program (CLIP), Barcelona Clinic Liver Cancer (BCLC), alpha-
fetoprotein levels (AFP)
*Some baseline (at time of diagnosis) clinical information were missing from patients’ medical records including (cirrhosis, 1; vascular invasion, 1; 
portal thrombosis, 1; extra-hepatic metastasis, 1; lymph node metastasis, 2; tumor involvement, 21; tumor nodularity, 23; tumor differentiation, 7; 
CLIP score, 21; OKUDA stage, 7; BCLC stage, 11; TNM stage, 25)
†
P value using chi-square test
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